相似文献
1
The metabolic basis of kidney cancer.
Semin Cancer Biol. 2013 Feb;23(1):46-55. doi: 10.1016/j.semcancer.2012.06.002. Epub 2012 Jun 13.
2
The genetic basis of kidney cancer: a metabolic disease.
Nat Rev Urol. 2010 May;7(5):277-85. doi: 10.1038/nrurol.2010.47.
3
Tuberous sclerosis complex protein 1 expression is affected by VHL Gene alterations and HIF-1α production in sporadic clear-cell renal cell carcinoma.
Exp Mol Pathol. 2016 Dec;101(3):323-331. doi: 10.1016/j.yexmp.2016.11.003. Epub 2016 Nov 12.
4
Re-evaluation of histological type by immunohistochemical and genetic study of transcription factors (TFE3 and TFEB) of VHL gene mutation-negative clear cell renal cell carcinoma and other special types of renal tumor.
Med Mol Morphol. 2011 Mar;44(1):46-51. doi: 10.1007/s00795-009-0478-3. Epub 2011 Mar 23.
5
The genetic basis of cancer of the kidney.
J Urol. 2003 Dec;170(6 Pt 1):2163-72. doi: 10.1097/01.ju.0000096060.92397.ed.
6
Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Oncogene. 2000 Nov 16;19(48):5435-43. doi: 10.1038/sj.onc.1203938.
7
Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization.
PLoS One. 2010 Dec 29;5(12):e15793. doi: 10.1371/journal.pone.0015793.
8
[Clinicopathologic and molecular genetic study of renal cell carcinoma occurring in teenagers].
Zhonghua Bing Li Xue Za Zhi. 2010 Sep;39(9):582-6.
9
Oncotargets in different renal cancer subtypes.
Curr Drug Targets. 2015;16(2):125-35. doi: 10.2174/1389450116666150126110632.
10
Hereditary kidney cancer syndromes.
Adv Chronic Kidney Dis. 2014 Jan;21(1):81-90. doi: 10.1053/j.ackd.2013.10.001.
引用本文的文献
1
Cooperative Role of Carbonic Anhydrase IX/XII in Driving Tumor Invasion and Metastasis: A Novel Targeted Therapeutic Strategy.
Cells. 2025 May 11;14(10):693. doi: 10.3390/cells14100693.
2
A Systematic Analysis of Expression and Function of RAS GTPase-Activating Proteins (RASGAPs) in Urological Cancers: A Mini-Review.
Cancers (Basel). 2025 Apr 28;17(9):1485. doi: 10.3390/cancers17091485.
3
Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted Therapies.
Genes (Basel). 2024 Dec 24;16(1):6. doi: 10.3390/genes16010006.
4
Function of NEK2 in clear cell renal cell carcinoma and its effect on the tumor microenvironment.
Medicine (Baltimore). 2024 May 17;103(20):e37939. doi: 10.1097/MD.0000000000037939.
5
Cellular senescence and metabolic reprogramming model based on bulk/single-cell RNA sequencing reveals PTGER4 as a therapeutic target for ccRCC.
BMC Cancer. 2024 Apr 11;24(1):451. doi: 10.1186/s12885-024-12234-5.
6
Preoperative Age and Its Impact on Long-Term Renal Functional Decline after Robotic-Assisted Partial Nephrectomy: Insights from a Tertiary Referral Center.
Medicina (Kaunas). 2024 Mar 11;60(3):463. doi: 10.3390/medicina60030463.
7
Metabolic alterations in hereditary and sporadic renal cell carcinoma.
Nat Rev Nephrol. 2024 Apr;20(4):233-250. doi: 10.1038/s41581-023-00800-2. Epub 2024 Jan 22.
8
Clinical Characteristics of Molecularly Defined Renal Cell Carcinomas.
Curr Issues Mol Biol. 2023 May 31;45(6):4763-4777. doi: 10.3390/cimb45060303.
9
A new glance at autophagolysosomal-dependent or -independent function of transcriptional factor EB in human cancer.
Acta Pharmacol Sin. 2023 Aug;44(8):1536-1548. doi: 10.1038/s41401-023-01078-7. Epub 2023 Apr 3.
10
Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma.
Nat Commun. 2023 Mar 27;14(1):1681. doi: 10.1038/s41467-023-37211-7.
本文引用的文献
1
Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
PLoS Genet. 2011 Oct;7(10):e1002312. doi: 10.1371/journal.pgen.1002312. Epub 2011 Oct 13.
2
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.
Nature. 2011 Oct 19;480(7375):94-8. doi: 10.1038/nature10539.
3
The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels.
Cancer Cell. 2011 Sep 13;20(3):315-27. doi: 10.1016/j.ccr.2011.07.018.
4
Characteristics of the coexistence of melanoma and renal cell carcinoma.
Cancer. 2010 Dec 15;116(24):5716-24. doi: 10.1002/cncr.25562.
5
Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization.
PLoS One. 2010 Dec 29;5(12):e15793. doi: 10.1371/journal.pone.0015793.
6
Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors.
J Urol. 2011 Jan;185(1):24-9. doi: 10.1016/j.juro.2010.08.092. Epub 2010 Nov 12.
7
Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.
Am J Surg Pathol. 2010 Sep;34(9):1295-303. doi: 10.1097/PAS.0b013e3181e8ce5b.
8
The genetic basis of kidney cancer: a metabolic disease.
Nat Rev Urol. 2010 May;7(5):277-85. doi: 10.1038/nrurol.2010.47.
9
Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma.
Am J Surg Pathol. 2010 Jun;34(6):757-66. doi: 10.1097/PAS.0b013e3181dd577e.
10
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
Ann Oncol. 2010 Sep;21(9):1834-1838. doi: 10.1093/annonc/mdq029. Epub 2010 Feb 12.
Zotero 插件